Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: Evaluation of the clinical course and treatment response.

The clinical features of patients with BP treated with DPP4is were initially more severe; however, during follow-up, a marked clinical improvement was noticed, especially among patients who had ceased the drug. Therefore, although withdrawal of the drug may not impose disease remission, it can alleviate the disease course and avert the need for treatment escalation.